Silexion Therapeutics Corp(SLXN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SLXN Silexion Therapeutics Corp

Trading 06-25 13:00:36 EDT

2.73

+0.03

+1.11%

High2.80	Low2.60	Vol10.61K
Open2.65	D1 Closing2.70	Amplitude7.41%
Mkt Cap2.90M	Tradable Cap2.89M	Total Shares1.06M
T/O28.38K	T/O Rate1.00%	Tradable Shares1.06M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SLXN","market":"US","secType":"STK","nameCN":"Silexion Therapeutics Corp","latestPrice":2.73,"timestamp":1782406835081,"preClose":2.7,"halted":0,"volume":10614,"delay":0,"changeRate":0.011111111111111039,"floatShares":1058700,"shares":1063117,"eps":-63.78105,"marketStatus":"Trading","change":0.03,"latestTime":"06-25 13:00:36 EDT","open":2.65,"high":2.8,"low":2.6,"amount":28384.417324799997,"amplitude":0.074074,"askPrice":2.8,"askSize":265,"bidPrice":2.68,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-63.78105,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1782417600000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":2.7,"preHourTrading":{"tag":"盘前","latestPrice":2.65,"preClose":2.7,"latestTime":"08:37 EDT","volume":425,"amount":1132.3938425000001,"timestamp":1782391044823,"change":-0.05,"changeRate":-0.018519,"amplitude":0.059259},"postHourTrading":{"tag":"盘后","latestPrice":2.6932,"preClose":2.7,"latestTime":"19:24 EDT","volume":574,"amount":1537.4428,"timestamp":1782343447506,"change":-0.0068,"changeRate":-0.002519,"amplitude":0.002519},"volumeRatio":0.12775},"requestUrl":"/m/hq/s/SLXN/tweets","defaultTab":"tweets","newsList":[{"id":"2646178028","title":"Analysts Are Bullish on Top Healthcare Stocks: Silexion Therapeutics (SLXN), Viking Therapeutics (VKTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2646178028","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646178028?lang=en_us&edition=fundamental","pubTime":"2026-06-25 00:50","pubTimestamp":1782319815,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Silexion Therapeutics (SLXN) and Viking Therapeutics...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-silexion-therapeutics-slxn-viking-therapeutics-vktx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-silexion-therapeutics-slxn-viking-therapeutics-vktx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4139","BK4585","BK4599","VKTX","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645649028","title":"Silexion Therapeutics Corp : Maxim Group Adjusts Target Price to $6 From $60 to Reflect 1-for-10 Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2645649028","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645649028?lang=en_us&edition=fundamental","pubTime":"2026-06-24 13:39","pubTimestamp":1782279551,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nFWN42V0WH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645836065","title":"Silexion wins Germany BfArM clearance to launch SIL204 Phase 2/3 pancreatic cancer trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2645836065","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645836065?lang=en_us&edition=fundamental","pubTime":"2026-06-23 20:40","pubTimestamp":1782218419,"startTime":"0","endTime":"0","summary":"Silexion won unconditional clearance from Germany’s BfArM to start its Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer.The authorization positions the company to launch the study in Germany alongside previously secured approval in Israel.First patient dosing is expected in the coming weeks, subject to site activation timelines.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nNDL7RcXSq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BKPKM429.USD","IE00BN0W2W23.USD","SG9999014013.SGD","IE00BGHQF748.EUR","SG9999014005.SGD","IE00B64PRP62.GBP","BK4588","BK4112","LU2095319765.USD","SLXN","LU0314104364.USD","IE00B3QW5Z07.USD","SG9999014021.USD","NDAQ","BK4585","LU2210150020.SGD","SG9999014039.USD","LU2210149790.SGD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645836053","title":"Silexion Therapeutics Corp - to Initiate Phase 2/3 Trial of Sil204 in Israel and Germany","url":"https://stock-news.laohu8.com/highlight/detail?id=2645836053","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645836053?lang=en_us&edition=fundamental","pubTime":"2026-06-23 20:40","pubTimestamp":1782218400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nTUA6641FH:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645360558","title":"Silexion Therapeutics Corp - Trial Approved Without Conditions Following Positive Ethics Committee Opinion in Germany","url":"https://stock-news.laohu8.com/highlight/detail?id=2645360558","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645360558?lang=en_us&edition=fundamental","pubTime":"2026-06-23 20:40","pubTimestamp":1782218400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nTUA6641FH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645022179","title":"Silexion Therapeutics presentation highlights SIL204 siRNA program targeting KRAS-driven pancreatic cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2645022179","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645022179?lang=en_us&edition=fundamental","pubTime":"2026-06-22 20:38","pubTimestamp":1782131887,"startTime":"0","endTime":"0","summary":"Silexion outlined SIL204, an siRNA designed to silence KRAS gene expression with dual delivery targeting primary pancreatic tumors and micrometastases.Program focus is locally advanced pancreatic cancer; KRAS mutations cited in 92% of cases, with SIL204 targeting more than 74% of PDAC KRAS mutations.Total addressable market estimate for localized advanced pancreatic cancer: U.S. about USD 2 billion; E.U. about USD 3 billion.Phase 2/3 trial plan: safety run-in to start mid-2026 with completion expected in Q2 2027; Phase 2 expansion to start Q3 2027.Phase 3 confirmatory segment targeted to start Q3 2030; interim results flagged for 2028 with potential sample size adjustment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therape","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDLbrnMYL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644760946","title":"Silexion Therapeutics management to attend BIO International Convention 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2644760946","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644760946?lang=en_us&edition=fundamental","pubTime":"2026-06-17 04:30","pubTimestamp":1781641857,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics management will attend the 2026 BIO International Convention in San Diego on June 22-25.One-on-one meetings with management are scheduled during the convention.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDLrPyMR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BKPKM429.USD","IE00BN0W2W23.USD","SG9999014013.SGD","IE00BGHQF748.EUR","SG9999014005.SGD","IE00B64PRP62.GBP","BK4588","BK4112","LU2095319765.USD","SLXN","LU0314104364.USD","IE00B3QW5Z07.USD","SG9999014021.USD","NDAQ","BK4585","LU2210150020.SGD","SG9999014039.USD","LU2210149790.SGD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643218270","title":"Silexion Therapeutics files to sell 859,609 ordinary shares for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2643218270","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643218270?lang=en_us&edition=fundamental","pubTime":"2026-06-13 04:10","pubTimestamp":1781295049,"startTime":"0","endTime":"0","summary":"16:08 EDT Silexion Therapeutics (SLXN) files to sell 859,609 ordinary shares for holders Published first on TheFly – the ultimate source for real-t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-files-to-sell-859609-ordinary-shares-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-files-to-sell-859609-ordinary-shares-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","SLXN","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639621796","title":"Silexion Therapeutics executes 1-for-10 reverse share split","url":"https://stock-news.laohu8.com/highlight/detail?id=2639621796","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639621796?lang=en_us&edition=fundamental","pubTime":"2026-05-29 19:02","pubTimestamp":1780052564,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics set a 1-for-10 reverse share split, effective May 28, 2026, subject to board confirmation tied to Nasdaq bid-price compliance.Authorized share capital to be consolidated to US$796,500 divided into 5,900,000 ordinary shares with a par value of US$0.135.Issued ordinary shares to consolidate to 407,471 from 4,074,710, based on the April 7, 2026 share count.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 29, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nNDL4LfKm2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639124336","title":"Silexion Therapeutics Corp trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2639124336","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639124336?lang=en_us&edition=fundamental","pubTime":"2026-05-29 07:50","pubTimestamp":1780012259,"startTime":"0","endTime":"0","summary":"19:50 EDT Silexion Therapeutics (SLXN) Corp trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-movi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-corp-trading-halted-news-pending-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-corp-trading-halted-news-pending-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638514000","title":"Silexion Therapeutics announces 1-for-10 reverse share split","url":"https://stock-news.laohu8.com/highlight/detail?id=2638514000","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638514000?lang=en_us&edition=fundamental","pubTime":"2026-05-26 20:30","pubTimestamp":1779798645,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics will execute a 1-for-10 reverse share split, effective after the May 28 market close.Shares start trading on a split-adjusted basis on Nasdaq at the May 29 open under ticker SLXN.Each 10 ordinary shares will convert into 1 share; par value rises to $0.135 from $0.0135.No fractional shares will be issued; DTC participants entitled to fractions will receive rounded-up whole shares.Move targets Nasdaq’s $1 minimum bid requirement, aiming to support listing compliance and future equity financing flexibility.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nNDLGXXDy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","SG9999014021.USD","SG9999014039.USD","LU0314104364.USD","BK4112","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","BK4585","NDAQ","BK4139","IE00BGHQF748.EUR","LU2095319765.USD","IE00BKPKM429.USD","BK4588","LU2210149790.SGD","SLXN","IE00BN0W2W23.USD","SG9999014013.SGD","LU2210150020.SGD","SG9999014005.SGD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638702514","title":"Silexion Therapeutics Announces 1-for-10 Reverse Share Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2638702514","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638702514?lang=en_us&edition=fundamental","pubTime":"2026-05-26 20:30","pubTimestamp":1779798601,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nTUA6VRR3K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636849250","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2636849250","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636849250?lang=en_us&edition=fundamental","pubTime":"2026-05-20 19:14","pubTimestamp":1779275695,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics  shares were up 180% in Wednesday premarket trading after the company reported a narrower Q1 loss.GCL Global  stock was 94% higher, a day after the company said its publishing subsidiary, 4Divinity, received an additional $10 million investment from ADATA Technology.Micware  stock was up 84%, recovering from a 25% decline in the previous session.BiomX  shares were 40% higher after plunging 18% in the previous session.WORK Medical Technology  stock was up 24% following a 38% drop in Tuesday's trading session.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GCL","BK4139","MWC","BK4198","WOK","PHGE","SLXN","BK4085"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636907303","title":"Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2636907303","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636907303?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:30","pubTimestamp":1779107401,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nTUA9ZRJ7D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635605339","title":"Silexion net loss widens 58.8% to USD 2.73 million in Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2635605339","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635605339?lang=en_us&edition=fundamental","pubTime":"2026-05-16 05:26","pubTimestamp":1778880384,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics posted a net loss of USD 2.73 million, widening 58.8% from the year-ago quarter.Operating loss widened to USD 2.75 million as operating expenses climbed to USD 2.75 million.Research and development expense more than doubled to USD 1.37 million, driven by higher subcontractor and consultant spending tied to toxicology studies, product development, and GMP manufacturing ahead of a planned human clinical trial expected in Q2 2026, subject to regulatory clearance.General and administrative expense rose 27.3% to USD 1.38 million on higher professional services costs related to operating as a public company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL42H8r6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635030432","title":"Silexion Therapeutics sells unregistered warrants for 3990184 shares at $0.5 each","url":"https://stock-news.laohu8.com/highlight/detail?id=2635030432","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635030432?lang=en_us&edition=fundamental","pubTime":"2026-05-16 04:34","pubTimestamp":1778877294,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics signed warrant inducement deal covering 1,995,092 existing warrants, with holders agreeing to exercise for cash at reduced exercise price of $0.5 per share.Transaction expected to generate about USD 1 million gross proceeds, with closing targeted around May 18, 2026.As consideration, company will issue unregistered Series C and Series D warrants to buy up to 3,990,184 ordinary shares at $0.5 per share, subject to shareholder approval.H.C. Wainwright to act as placement agent, earning 7% cash fee plus 1% management fee, with placement agent warrants for up to 139,656 ordinary shares at $0.625 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL6SsQYB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635842380","title":"Silexion Therapeutics says warrant exercises raise USD 1 million gross proceeds","url":"https://stock-news.laohu8.com/highlight/detail?id=2635842380","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635842380?lang=en_us&edition=fundamental","pubTime":"2026-05-15 20:27","pubTimestamp":1778848060,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics entered definitive agreements for immediate cash exercise of outstanding warrants covering 1,995,092 ordinary shares at reduced exercise price of USD 0.5 per share.Gross proceeds expected at about USD 1 million; closing expected on or about May 18, 2026.In exchange, investors to receive unregistered Series C warrants for 2,045,000 shares and unregistered Series D warrants for 1,945,184 shares, each exercisable at USD 0.5 per share subject to shareholder approval.Series C warrants set to expire five years from later of shareholder approval or effectiveness of resale registration statement; Series D warrants set to expire 24 months from same later date.Company agreed to file resale registration statement for shares underlying new warrants.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL8ys9Lz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","LU2210149790.SGD","SG9999014013.SGD","SLXN","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","LU0314104364.USD","LU2095319765.USD","IE00BGHQF748.EUR","SG9999014039.USD","BK4588","NDAQ","SG9999014021.USD","BK4585","SG9999014005.SGD","IE00BKPKM429.USD","BK4112","LU2210150020.SGD","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635273084","title":"Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds","url":"https://stock-news.laohu8.com/highlight/detail?id=2635273084","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635273084?lang=en_us&edition=fundamental","pubTime":"2026-05-15 20:27","pubTimestamp":1778848020,"startTime":"0","endTime":"0","summary":"Grand Cayman, May  15, 2026  (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) the","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/15/3295817/0/en/Silexion-Therapeutics-Announces-Exercise-of-Warrants-for-1-Million-Gross-Proceeds.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN","BK4539","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635748156","title":"Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for Sil204 in Kras-Driven Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2635748156","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635748156?lang=en_us&edition=fundamental","pubTime":"2026-05-14 21:27","pubTimestamp":1778765220,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nTUA21NVWW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635748295","title":"Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2635748295","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635748295?lang=en_us&edition=fundamental","pubTime":"2026-05-14 21:27","pubTimestamp":1778765220,"startTime":"0","endTime":"0","summary":"Preliminary results from a preclinical study demonstrated statistically significant increase in MHC-I expression following SIL204 treatment in human pancreatic and non-small cell lung cancer cells har","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/14/3295074/0/en/Silexion-Therapeutics-Reports-Positive-Preliminary-Immunotherapy-Findings-for-SIL204-in-KRAS-Driven-Pancreatic-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LENZ","BK4139","BK4539","SLXN"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.silexion.com","stockEarnings":[{"period":"1week","weight":-0.069},{"period":"1month","weight":-0.46},{"period":"3month","weight":-0.7939},{"period":"6month","weight":-0.8821},{"period":"1year","weight":-0.978},{"period":"ytd","weight":-0.8594}],"compareEarnings":[{"period":"1week","weight":-0.0104},{"period":"1month","weight":-0.0166},{"period":"3month","weight":0.1366},{"period":"6month","weight":0.0622},{"period":"1year","weight":0.2084},{"period":"ytd","weight":0.0753}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Moringa Acquisition Corp does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses. The company focuses on pursuing opportunities in technology-based businesses or industries in Israel. Moringa Acquisition Corp was incorporated in 2020 and is based in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.016335},{"month":2,"riseRate":0.6,"avgChangeRate":-0.095221},{"month":3,"riseRate":0.8,"avgChangeRate":-0.040641},{"month":4,"riseRate":0.6,"avgChangeRate":-0.119987},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.024382},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.104607},{"month":7,"riseRate":1,"avgChangeRate":0.055675},{"month":8,"riseRate":0.4,"avgChangeRate":-0.277749},{"month":9,"riseRate":0.6,"avgChangeRate":-0.230878},{"month":10,"riseRate":0.4,"avgChangeRate":-0.091257},{"month":11,"riseRate":0.4,"avgChangeRate":-0.018649},{"month":12,"riseRate":0.2,"avgChangeRate":-0.12005}],"exchange":"NASDAQ","name":"Silexion Therapeutics Corp","nameEN":"Silexion Therapeutics Corp"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Silexion Therapeutics Corp(SLXN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Silexion Therapeutics Corp(SLXN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Silexion Therapeutics Corp,SLXN,Silexion Therapeutics Corp股票,Silexion Therapeutics Corp股票老虎,Silexion Therapeutics Corp股票老虎国际,Silexion Therapeutics Corp行情,Silexion Therapeutics Corp股票行情,Silexion Therapeutics Corp股价,Silexion Therapeutics Corp股市,Silexion Therapeutics Corp股票价格,Silexion Therapeutics Corp股票交易,Silexion Therapeutics Corp股票购买,Silexion Therapeutics Corp股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Silexion Therapeutics Corp(SLXN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Silexion Therapeutics Corp(SLXN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction